Adalimumab does not cause weight gain in patients with psoriasis in the first year of treatment-Reference-Cited by-同舟云学术

Adalimumab does not cause weight gain in patients with psoriasis in the first year of treatment

Published:2023-06-03 Issue:10 Volume:48 Page:1169-1171
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:

Author:

Schwarz Christopher W¹²³^ORCID,Loft Nikolai¹³^ORCID,Kaur-Knudsen Diljit¹²,Zachariae Claus¹²³^ORCID,Skov Lone¹²³^ORCID

Affiliation:

1. Department of Dermatology and Allergy

2. Department of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark

3. Copenhagen Research Group for Inflammatory Skin, Copenhagen University Hospital, Herlev and Gentofte , Copenhagen , Denmark

Abstract

Treatment of psoriasis with adalimumab has been associated with weight gain; however, data are sparse. We conducted a cohort study in Danish patients with psoriasis treated with adalimumab, secukinumab and ustekinumab. After 1 year of treatment, we found no significant weight gain and the three treatments were comparable with regards to change in bodyweight. Therefore, our study does not support that adalimumab results in weight gain.

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llad195/50887434/llad195.pdf

Reference8 articles.

1. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study;Gisondi;J Eur Acad Dermatol Venereol,2008

2. Impact of TNF-α inhibitors on body weight and BMI: a systematic review and meta-analysis;Patsalos;Front Pharmacol,2020

3. Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis;Saraceno;Pharmacol Res,2008

4. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis;Tan;Australas J Dermatol,2013

5. Simultaneous inference in general parametric models;Hothorn;Biom J,2008